Biomunex Pharmaceuticals Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $3.48M

  • Investors
  • 5

Biomunex Pharmaceuticals General Information

Description

Developer of immunotherapies designed to deliver therapeutics in the area of immuno-oncology. The company's immunotherapies offer to develop drug candidates with high anti-tumor potential, superior manufacturability, and optimal drug-like properties, enabling biotechnology companies to format antibodies from any pair of monospecific monoclonal antibodies as building blocks in a timely and cost-effective manner.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 27, rue du Faubourg Saint Jacques
  • 75014 Paris
  • France

Biomunex Pharmaceuticals Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biomunex Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Grant 03-Nov-2021 $3.48M 00.000 Completed Generating Revenue
5. Later Stage VC (Series A) 16-Feb-2021 00.000 00.000 000.00 Completed Generating Revenue
4. Seed Round Completed Startup
3. Accelerator/Incubator Completed Startup
2. Grant 01-Jan-2016 Completed Startup
1. Grant 01-Jan-2014 Completed Startup
To view Biomunex Pharmaceuticals’s complete valuation and funding history, request access »

Biomunex Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.000000 000.0 000.0 00 000.0 00.00
To view Biomunex Pharmaceuticals’s complete cap table history, request access »

Biomunex Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immunotherapies designed to deliver therapeutics in the area of immuno-oncology. The company's immunotherap
Drug Discovery
Paris, France
14 As of 2023
00.000
0000000000 00.000

000000

at nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa
0000 000000000
New York, NY
00 As of 0000
00000
00000 0000-00-00
00000000000 00000

00 000

u fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
0000000000000
Durham, NC
000 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biomunex Pharmaceuticals Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Volastra Venture Capital-Backed New York, NY 00 00000 00000000000 00000
G1 Therapeutics Formerly VC-backed Durham, NC 000 00000 00000000 00000
Ona Therapeutics Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
Loxo Oncology Formerly VC-backed Stamford, CT 00 00000 000000&0 00000
Ability Pharma Venture Capital-Backed Barcelona, Spain 00 000.00 0000000000 0 000.00
You’re viewing 5 of 11 competitors. Get the full list »

Biomunex Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Pierre-Emmanuel Gerard MD Founder, Chief Executive Officer & President
Stéphane Milot Financial Advisor, Chief Administrative Officer & Chief Financial Officer
Simon Plyte Ph.D Chief Scientific Officer & Member of Scientific Advisory Board
You’re viewing 3 of 6 executive team members. Get the full list »

Biomunex Pharmaceuticals Board Members (7)

Name Representing Role Since
Alain Dublin Self Board Member 000 0000
Dragan Grabulovski Ph.D Self Board Observer 000 0000
Grace Yeh Ph.D Onward Therapeutics Board Member 000 0000
Jordi Esclusa AEC Partners Board Member 000 0000
Philippe de Lavenne MD Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Biomunex Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biomunex Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
French Government Government 000 0000 000000 0
Onward Therapeutics Corporation Minority 000 0000 000000 0
L'Agence Nationale de la Recherche Government 000 0000 000000 0
Bpifrance Sovereign Wealth Fund 000 0000 000000 0
Agoranov Accelerator/Incubator Minority 000 0000 000000 0
To view Biomunex Pharmaceuticals’s complete investors history, request access »

Biomunex Pharmaceuticals FAQs

  • When was Biomunex Pharmaceuticals founded?

    Biomunex Pharmaceuticals was founded in 2014.

  • Who is the founder of Biomunex Pharmaceuticals?

    Pierre-Emmanuel Gerard MD, Jean-Pierre Mach, and Geoffroy Ribains are the founders of Biomunex Pharmaceuticals.

  • Who is the CEO of Biomunex Pharmaceuticals?

    Pierre-Emmanuel Gerard MD is the CEO of Biomunex Pharmaceuticals.

  • Where is Biomunex Pharmaceuticals headquartered?

    Biomunex Pharmaceuticals is headquartered in Paris, France.

  • What is the size of Biomunex Pharmaceuticals?

    Biomunex Pharmaceuticals has 14 total employees.

  • What industry is Biomunex Pharmaceuticals in?

    Biomunex Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Biomunex Pharmaceuticals a private or public company?

    Biomunex Pharmaceuticals is a Private company.

  • What is Biomunex Pharmaceuticals’s current revenue?

    The current revenue for Biomunex Pharmaceuticals is 000000.

  • How much funding has Biomunex Pharmaceuticals raised over time?

    Biomunex Pharmaceuticals has raised $6.41M.

  • Who are Biomunex Pharmaceuticals’s investors?

    French Government, Onward Therapeutics, L'Agence Nationale de la Recherche, Bpifrance, and Agoranov have invested in Biomunex Pharmaceuticals.

  • Who are Biomunex Pharmaceuticals’s competitors?

    Volastra, G1 Therapeutics, Ona Therapeutics, Loxo Oncology, and Ability Pharma are some of the 11 competitors of Biomunex Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »